Advances in proteomic technology have enabled contaminant proteins to be identified from complex protein mixtures. The purity of two purified urinary gonadotrophin products, human menopausal gonadotrophin (u-HMG) and human FSH (u-hFSH), was compared with a preparation of recombinant human FSH (r-hFSH). After separation by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE), western blot analysis showed that the recombinant preparation contained only FSH, whereas the urine-derived preparations exhibited several non-FSH or LH-related bands. These urinary components were further investigated by a proteomic approach using two-dimensional SDS-PAGE followed by mass spectrometric identification. The proteomic approach detected a total of 23 non-gonadotrophin-related proteins, at variable levels in different batches of the urine-derived preparations. Of these, 16 co-purified proteins have not been previously reported to be present in urine-derived gonadotrophins. These results indicate that the process used to purify urinary gonadotrophins may not remove all non-gonadotrophin proteins. By using a comprehensive proteomic approach, it has been shown that the recombinant FSH preparation has greater purity than either of the urine-derived preparations.
Introduction
This study used a comprehensive analytical approach to assess the purity and inter-batch quality of current formulations of commercially available purified urinary gonadotrophins and compare them with an r-hFSH preparation. This exploratory analysis includes samples from only a few batches, as a previous analysis has documented the lack of contaminants in r-hFSH and the presence and variability of contaminants in urinary human (u-h)FSH in a larger number of batches (Lispi et al., 2006) .
Materials and methods

Source of material
Between 19 and 30 vials from six commercial batches of urinary human menopausal gonadotrophin (u-HMG) 75 IU (Menopur; Ferring Pharmaceuticals, Denmark) and 14 and 73 vials from three batches of u-hFSH 75 IU (Bravelle; Ferring Pharmaceuticals, Denmark) were used. Both products are manufactured as a lyophilized powder in a single dose vial. Each vial is accompanied by a vial of sterile diluent containing 1 ml of 0.9% sodium chloride injection, USP. According to the supplier's product information, each vial of the u-hFSH product is overfilled to contain 82.5 IU to deliver the 75 IU dose; no overfill data are available for the u-HMG product.
Between 17 and 28 cartridges from one batch of solutionfor-injection (GONAL-f; Merck Serono S.A. -Geneva, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany) were obtained directly from the manufacturing sites for each dose strength of r-hFSH (300 IU/0.5 ml, 450 IU/0.75 ml and 900 IU/1.5 ml; Table 1 ). In-house FSH and LH reference standards were used (Merck Serono S.A. -Geneva).
Analytical methods
Gel electrophoresis
Gel electrophoresis was performed using a pre-cast 4-12% bistris polyacrylamide gel (NuPAGE Novex; Invitrogen, Carlsbad, CA, USA), at 200 V for 35-40 min at room temperature.
Samples in reducing conditions were loaded in each lane at 6 IU as well as molecular weight markers (Mark 12 -Invitrogen Corporation, Carlsbad, CA, USA). Following electrophoresis, protein bands were visualized by silver staining (PlusOne; Amersham Biosciences, Uppsala, Sweden), according to the manufacturer's instructions.
Western blot analysis
After separation by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE), proteins were transferred onto a nitrocellulose membrane by electric transfer. The membranes were incubated in blocking solution, and then incubated with a specific commercial antibody according to the test to be performed.
To detect the FSH-, LH-and human chorionic gonadotrophin (HCG)-related bands in u-HMG and r-hFSH, the following primary antibodies were used: a polyclonal antibody directed against FSH/LH (code AB928; Chemicon International, Temecula, CA, USA); a polyclonal antibody to β-HCG (code 3AR393; Scantibodies Laboratory, Santee, CA, USA); a monoclonal antibody to LH (clone 19/1; Merck Serono S.A. -Geneva); a monoclonal antibody to FSH (clone 9/14;
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Isoelectric focusing
This method was performed as described in a previous publication (Lispi et al., 2006) . Briefly, a commercial dried polyacrylamide gel was rehydrated in a solution buffered to create a pH gradient of 2.6-6.5. After transfer to a nitrocellulose membrane, immunoblotting and detection were performed to reveal proteins.
Determination of total protein content of drug preparations
The total protein content of u-HMG and r-hFSH was determined by Bradford assay using the Coomassie Plus Protein Assay Kit (Pierce, Rockford, IL, USA) according to the manufacturer's instructions for the Micro Microplate Protocol, with a working range of 1-25 µg. Bovine serum albumin was used as standard.
Immunoassays
Methods for quantification of gonadotrophins, EGF and EDN were all performed as described previously (Lispi et al., 2006) , using commercial kits (a diagnostic enzyme-linked fluoroimmunometric assay, an EGF DEG00-Quantikine immunoassay and an EDN enzyme-linked immunosorbent kit respectively).
FSH in-vivo bioassay
This method was described in detail in a previous publication (Lispi et al., 2006) . Each sample was tested independently in triplicate, and the activity of FSH in vivo was assessed by the rat ovarian weight gain method of Steelman and Pohley (1953) .
During the test, samples were handled as follows. Each vial of u-HMG and u-hFSH was reconstituted with 1 ml of diluent contained in the package (NaCl 0.9%) using a sterile syringe. The reconstituted sample was withdrawn from the original vial within 60 s of reconstitution, using the same syringe used in the reconstitution phase. The reconstituted solution was injected directly into the tube containing phosphate buffer solution and 0.1% bovine serum albumin. The resulting solution was diluted to obtain three doses of FSH (0.33, 0.66 and 1.33 IU/ml) corresponding to the final cumulative doses of FSH of 1, 2 and 4 IU per rat; the volume of solution injected was 3 ml for each dose. Each dose sample was assayed in triplicate and compared with the FSH in-house reference standard, to provide an estimated ratio of bioactivity for each preparation. For measurement of u-hFSH in-vivo bioactivity, a urinary-derived FSH standard was used and for measurement of r-hFSH in-vivo bioactivity, a recombinant-derived FSH standard was used; both were calibrated against international standards (Lispi et al., 2006) .
Size exclusion-high performance liquid chromatography
Chromatography was performed using a size exclusion-high performance liquid chromatography (SE-HPLC) column (Biosep S2000; Tosoh Bioscience GmbH, Stuttgart, Germany) at room temperature, using a sodium phosphate/sodium sulphate buffer at pH 6.7, at a flow rate of 1 ml/min for FSH content and 0.7 ml/ min for FSH purity. Detection was carried out at 214 nm. Protein content and purity were determined by calibration against an inhouse reference standard, quantified by amino acid analysis.
Reverse phase-high performance liquid chromatography
The reverse phase-high performance liquid chromatography (RP-HPLC) method has been described in a previous publication (Bassett and Driebergen, 2005) .
The two subunits of r-hFSH were separated, and the peaks relative to the oxidized alpha subunit were quantified as a proportion of the intact alpha subunit. To assess FSH and LH content, the beta subunits of FSH and LH were separated, and the peaks relative to each subunit were quantified by reference to FSH and LH in-house reference standards.
Two-dimensional SDS-PAGE and mass spectrometry
Two batches of both u-HMG and u-hFSH were analysed. A sample (of approximately 1050-1875 IU) of each urinary product was pretreated by ultracentrifugation to remove nonprotein product excipients. Approximately 100-400 µg of protein were loaded onto a two-dimensional (2D) SDS-PAGE gel. Proteins were separated on a first dimension according to their isoelectric point (pI) at 86,000 HV, and then on a second dimension according to their molecular weight. Following 2D separation, the gels were stained by silver or Coomassie blue staining. Detected proteins were removed from the gel using a gel cutter (PROTEINEERsp; Bruker Daltonik GmbH, Bremen, Germany), washed, reduced, alkylated and dehydrated automatically with a MassPrep robot (Micromass; Manchester, UK). The gel pieces were digested with porcine trypsin (Promega; Madison, WI, USA). The resulting tryptic peptides were extracted with 60% acetonitrile in 5% formic acid and analysed by mass spectrometry (MS), either with a matrixassisted laser desorption ionization (MALDI) or electrospray (ES) ionization source.
Mass spectrometry
MALDI time-of-flight (TOF) MS measurements were acquired using the Ultraflex TOF/TOF mass spectrometer (Bruker Daltonik GmbH, Bremen, Germany). The samples were prepared by standard dried droplet preparation on stainless steel MALDI targets using alpha-cyano-4-hydroxycinnamic acid as matrix (Luche et al., 2004 
Database searches to identify proteins
Monoisotopic peptide masses were automatically annotated using Flexanalysis 2.0 software (Bruker Daltonics, USA) and used for database searches.
Proteins were identified by peptide mass fingerprinting using the MASCOT program (Matrix Science, London, UK) matching against peptides from the SwissProt and TrEMBL databases for all species [see http://www.ebi.ac.uk/uniprot/ (accessed 6 July 2009)]. One missed proteolytic cleavage per peptide was allowed and variable modifications, such as carbamidomethylation for cysteine and oxidation for methionine, were taken into account. For MALDI-TOF, a mass tolerance of 50 ppm was used, and for NanoLC-MS/MS, a fragment tolerance of 0.2 Da was used.
Results
SDS-PAGE to assess purity level of HMG, urinary FSH and recombinant FSH
The u-HMG, u-hFSH and r-hFSH preparations were analysed by 4-12% bis-tris gel electrophoresis and silver staining to visualize the protein profile (Figures 1 and 2 ). All preparations showed the presence of a protein band at a molecular weight of approximately 22 kDa, corresponding to the FSH, LH and HCG reduced alpha and FSH beta subunits. The band present in u-HMG batches at 33 kDa corresponded to the HCG beta subunit. All batches of urinary products (u-HMG and u-hFSH) presented additional multiple protein bands at molecular weights greater than 36 kDa (Figures 1 and 2) . Apart from the major FSH band, no other bands were detected in the recombinant preparations.
Western blot to compare protein profiles of HMG and recombinant FSH
The u-HMG and r-hFSH preparations were also analysed by western blot using both polyclonal and monoclonal antibodies to visualize the FSH, LH and HCG protein profiles. Western blot analysis was not performed on u-hFSH as immunoassay results showed that LH and HCG were not present in sufficient quantities.
Western blot with polyclonal antibody reactive to the whole FSH molecule, and, according to the manufacturer, crossreactive with LH, gave three main bands in the u-HMG samples and only one in the r-hFSH samples ( Figure 3A) . The band at a molecular weight of approximately 22 kDa corresponds to the reduced alpha and beta subunits of FSH. The two additional bands identified in the u-HMG samples at approximately 20 and 33 kDa correspond to LH and HCG respectively. Additional bands, visible at approximately 50 kDa and higher molecular weights, may be assignable to aggregated FSH, which has recently been reported to be present in pituitary-derived FSH (Bousfield et al., 2008) .
Using a monoclonal antibody specific for the FSH beta subunit ( Figure 3B ), it was confirmed that only the 22 kDa bands were assignable to FSH. Some non-specific signals were present at higher molecular weights and can be assigned to aggregated FSH.
Using a polyclonal antibody to HCG ( Figure 3C ) and a monoclonal antibody to LH ( Figure 3D ), it was confirmed that the bands at 33 kDa and 20 kDa in the u-HMG samples were the HCG and LH beta subunits respectively.
Isoform profiles of HMG, urinary FSH and recombinant FSH
Isoform profiles for the u-HMG, u-hFSH and r-hFSH preparations were determined (Figures 4 and 5) . The urinary preparations showed an isoform range of pI 3.0-5.2. The recombinant preparation showed an isoform range of pI 3.5-6.0. The difference in isoform profile between urinary and recombinant FSH products was also clearly seen.
Total protein content of HMG and recombinant FSH
The total protein content was determined by Bradford assay ( Table 2 ). The mean protein content and between-batch variability [expressed as coefficient of variation (CV)] were 11.85 µg and 24.6% (n = 6) respectively for u-HMG 75 IU, and 76.7 µg and 2.9% (n = 3) respectively for r-hFSH.
The r-hFSH batches used in the present study were analysed previously (Lispi et al., 2006) . Between-batch variability in protein content (expressed as CV) was 1.9% (n = 8) for the r-hFSH solution for injection.
FSH content of HMG, urinary FSH and recombinant FSH
The amount of FSH protein in u-HMG, u-hFSH and r-hFSH was assessed using SE-HPLC and RP-HPLC (Table 3) . For u-HMG, the RP-HPLC method was used (as this separates FSH from LH and HCG), and the mean FSH protein content per container and between-batch variability (expressed as CV) Article -Additional impurities in urinary-derived gonadotrophins -R Bassett et al.
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RBMOnline ® were 7.49 µg and 3.35% (n = 5) respectively. The mean FSH protein content was 6.56 µg per container for u-hFSH (n = 2), and 48.90 µg/ml (normalized value = 6.11 µg/75 IU) for r-hFSH (n = 2).
FSH immunoactivity of HMG, urinary FSH and recombinant FSH
The FSH immunoactivity of the three gonadotrophins was assessed using a commercially available FSH immunoassay ( Table 4) . The between-batch variability (expressed as CV) for FSH immunoactivity was 6.3% for u-HMG (n = 6) and 3.3% for r-hFSH (n = 4). Values for mean FSH immunoactivity were 36.9 IU/ml for u-HMG, 39.1 IU/ml for u-hFSH, and 398.5 IU/ ml (normalized value = 49.8 IU/75 IU biopotency) for r-hFSH.
The r-hFSH batches used in the present study were analysed previously (Lispi et al., 2006) . Between-batch variability (expressed as CV) in immunoactivity was 2.5% (n = 8) for r-hFSH solution for injection.
Evaluation of delivered dose of HMG and urinary FSH
The FSH bioactivity for urine-derived HMG and FSH was assessed by an in-vivo bioassay. The delivered dose of FSH, estimated by preparing each sample according to the product leaflet, and the percentage recovery of FSH potency, evaluated by comparing the delivered dose to the claimed potency, are shown in Table 5 . The total content of the vial was also assessed and compared with the claimed potency.
The mean delivered FSH bioactivity for u-HMG 75 IU was 64 IU, and for u-hFSH 75 IU was 66 IU. The between-batch variability (expressed as CV) for delivered FSH bioactivity in u-HMG 75 IU was 3.3% (n = 5). The mean percentage recovery of delivered FSH for u-HMG was 85%, and for u-hFSH was 88%.
The between-batch variability (expressed as CV) for total FSH bioactivity in batches of u-HMG 75 IU was 3.7% (n = 6). The mean percentage recovery per vial of FSH bioactivity was 89% for u-HMG and 92% for u-hFSH (Table 6 ).
This in-vivo bioassay was not performed for r-hFSH, as it had been carried out previously and is reported in Lispi et al. (2006) .
LH and HCG content of HMG and urinary FSH
Commercially available immunoassays were used to quantify additional gonadotrophins (LH or HCG) in each urinary preparation ( Table 7) . For u-HMG 75 IU, the mean LH content and between-batch variability were 0.47 IU and 24.8% (n = 6) respectively and the mean HCG content and between-batch variability were 11.3 IU and 13.9% (n = 6) respectively. For u-hFSH, the mean LH and HCG content were 0.0089 IU/vial and 0.035 IU/vial respectively. No traces of other gonadotrophins were present in the recombinant preparations analysed.
Protein impurity content of HMG and urinary FSH
Commercially available immunoassays were used to determine the potential presence of the protein contaminants, EGF and EDN. EGF was not detected in the u-hFSH or u-HMG tested, whereas EDN was present in all urinary batches tested (Table 8) .
SE-HPLC to assess the purity of u-hFSH and r-hFSH samples
The presence of high molecular weight (HMW) proteins was assessed in u-hFSH and r-hFSH batches using an SE-HPLC method to assess the purity. HMW proteins were present in the two u-hFSH batches at 1.31 and 5.26%, but were absent from r-hFSH. These HMW proteins are probably related to the impurities observed in u-hFSH (Figure 1) .
Evaluation of oxidation level of HMG, urinary FSH and recombinant FSH
An RP-HPLC method was used to evaluate the oxidation level of u-HMG, u-hFSH and r-hFSH, and mean levels of oxidized gonadotrophin were 49.0, 51.0 and 1.6% respectively ( Table 9) .
Identification of non-gonadotrophin proteins in u-HMG and u-hFSH using electrophoresis and MS
After 2D gel electrophoresis (Figure 6 ), all proteins found to be present in the molecular weight range of approximately 25-100 kDa in u-HMG and u-hFSH were analysed by MS (ES-MS-MS and MALDI-MS), and identified from internationally available databases (Table 10 ).
In both batches of u-HMG the presence of the HCG beta subunit was confirmed. Non-gonadotrophin protein impurities were identified in both batches of both urinary products ( Table 10) . The most abundant proteins found in both batches of u-HMG were plasma serine protease inhibitor (protein C inhibitor), insulin-like growth factor binding protein 7 (IGFBP7), alpha-2-antiplasmin and apolipoprotein D. Plasma serine protease inhibitor (protein C inhibitor) and alpha-2-antiplasmin were also found in both batches of u-hFSH.
Discussion
Using a combination of highly sensitive analytical techniques, it is now possible to characterize fully the quality and precise composition of commercially available gonadotrophins. This study provides a comprehensive analytical comparison of two urinary gonadotrophin products and compares the profiles with that of a recombinant gonadotrophin product. After separation by SDS-PAGE, western blot analysis showed that the recombinant preparation contained only FSH, whereas the urine-derived preparations exhibited several non-FSH or LHrelated bands. ND, not determined. The between-batch variability (expressed as coefficient of variation) for delivered FSH bioactivity in u-HMG 75 IU was 3.3% (n = 5). The between-batch variability (expressed as coefficient of variation) for total FSH bioactivity in batches of u-HMG 75 IU was 3.7% (n = 6). It has been shown that recombinant FSH has high product purity with no other detectable proteins, together with a uniform isoform profile and low oxidation level (1.6%). This confirms previous findings showing that r-hFSH preparations consistently deliver the expected dose from batch to batch, free of undetectable proteins (Bassett and Driebergen, 2005; Lispi et al., 2006) .
The results show that, like many urine-derived gonadotrophins (Giudice et al., 1994 (Giudice et al., , 2001 van de Weijer et al., 2003; , u-HMG contains additional protein contaminants which vary in both identity and quantity between batches. Nongonadotrophin proteins were also found in u-hFSH. Using HPLC, specific immunoassays, 2D-gel electrophoresis and ES-MS, 24 urine-derived protein contaminants were identified in u-HMG and u-hFSH, including 16 contaminants not previously described. Previously published details of the purification process have suggested that similar co-purified proteins should be found in each of these two products as they share similar extraction and purification processes (Reichl et al., 2002; Wolfenson Band et al., 2006) . However, the MS results indicate that the contaminants present in u-HMG and u-hFSH are quite different. Although both products contain protein C inhibitor, leukocyte elastase inhibitor, alpha-2-antiplasmin and IGFBP7, u-HMG also contains human serum albumin together with many other proteins that are not present in u-hFSH (Table 10) .
Conversely, the hypothetical protein FLJ13710 is only present in u-hFSH.
Previous studies have indicated the presence of as yet uncharacterized non-gonadotrophin proteins in urinary gonadotrophins (van de Weijer et al., 2003) . The current study enabled identification of some of these co-purified proteins. IGFBP7 was highly abundant in both batches of u-HMG tested, and was identified in one batch of u-hFSH. IGFBP7 is secreted into the follicular fluid and may inhibit granulosa cell differentiation by suppressing oestrogen production (Tamura et al., 2007) . Alpha-2-antiplasmin was detected in both batches of u-hFSH and u-HMG in this study. Alpha-2-antiplasmin inactivates plasmin, which is involved in early follicular responses to ovulatory stimuli (Tsafriri et al., 1989) .
In addition to reporting the identification of several co-purified proteins in the urinary gonadotrophin preparations that were not identified previously, the study confirmed the presence of those previously found in u-HMG, such as leukocyte elastase inhibitor, plasma serine protease (protein C) inhibitor and zinc-alpha2-glycoprotein (van de Weijer et al., 2003) . With the u-HMG preparation reported to comprise no more than 70% gonadotrophin protein (van de Weijer et al., 2003) , it is estimated that most of the remaining 30% non-gonadotrophin proteins distributed in the molecular weight range 25-100 kDa Proteins previously identified as contaminants of u-HMG (van de Weijer et al., 2003) . b Proteins previously listed as contaminants (Herrler and Beneke, 2008) . Protein previously identified as a contaminant of u-hFSH (Lispi et al., 2006). have been identified (Figures 1 and 2) . The biological relevance of many of these protein impurities remains unknown, although studies in mice have demonstrated that gonadotrophins derived from urine may have negative effects on gene expression during the peri-implantation period (Sibug et al., 2005 (Sibug et al., , 2007 . In addition, a serine protease inhibitor has been shown to inhibit sperm penetration of hamster oocytes (Moore et al., 1993) and an elastase inhibitor complex was associated with a poorer blastocyst development rate and a higher number of arrested embryos (Zorn et al., 2004) . Furthermore, it has been shown that urinary and recombinant gonadotrophins induce differing patterns of cumulus cell protein expression in patients undergoing IVF cycles (Hamamah et al., 2006) .
The glycoprotein EDN is a common contaminant of commercial urinary gonadotrophin preparations (Kauffman et al., 1999) . Indeed, concentrations of 96 ± 60 ng/vial have been reported in preparations of u-HMG (Menogon; Ferring) (Kauffman et al., 1999) . Although concentrations were lower than those present in Menogon, EDN was detected in both u-hFSH and u-HMG in this study (0.70-2.33 ng/vial). High concentrations of hyperglycosylated EDN have been reported to be present in the urine of post-menopausal women with ovarian cancer, but this was not specifically investigated in this study (Ye et al., 2006) . EDN has also been shown to have a putative inhibitory effect on mouse oocyte maturation (Sakakibara et al., 1991 (Sakakibara et al., , 1992 .
EGF was not detected in either u-hFSH or u-HMG. This is believed to be because the purification process is able to remove EGF but not EDN from urinary gonadotrophin preparations.
The compositional analysis confirmed previous findings that FSH and HCG are the major gonadotrophins in u-HMG (van de Weijer et al., 2003) , and demonstrated that u-hFSH contained only trace amounts of both LH and HCG.
Both u-HMG and u-hFSH contained 49-51% of oxidized protein. Interestingly, this is greater than the 30-40% of oxidized protein previously reported in urinary gonadotrophins, and not surprisingly considerably higher than that reported for recombinant FSH in this study (<2%). The oxidized gonadotrophin content presumably reflects the oxidative stress of the rigorous extraction and purification processes to which all urine-derived products are subjected. However, the presence of non-gonadotrophin proteins indicates that thorough processing is unable to eliminate all unwanted proteins from urinary preparations. Moreover, the high levels of oxidation observed in u-HMG and u-hFSH suggest that associated nongonadotrophin proteins may also be oxidized. As oxidation alters the immunogenicity of therapeutic proteins (Hermeling et al., 2004) this could, theoretically, lead to undesired immunogenicity of non-gonadotrophin proteins in urinary preparations.
It was shown that the isoform profile of urinary gonadotrophin preparations was more acidic (pI 3.0-5.2), than that of the recombinant product (pI 3.5-6.0), which is consistent with many previous findings. More acidic isoforms are released during the early follicular phase of the menstrual cycle while more basic isoforms, with high in-vivo activity and shorter half-life, are released in the mid-cycle phase (Wide and Bakos, 1993; Flack et al., 1994; Anobile et al., 1998) . Post-menopausal women have more acidic FSH glycoforms than women at any stage of the menstrual cycle (Anobile et al., 1998) . Only 17% of glycoforms following the menopause have a pI >4.3, compared with approximately 50% at mid-cycle, and 36, 37 and 29% at early-to-mid-follicular, late follicular and luteal phases respectively (Anobile et al., 1998) .
In this study, two techniques were used to assess protein content: the Bradford assay and HPLC-based methods. The Bradford method is generally more suitable for unknown proteins and complex mixtures such as urine-derived gonadotrophin preparations. Although this method is not generally used to measure the protein content in purified preparations of urinary FSH or r-hFSH, which are more suited to HPLC methods, it does allow an assessment of total protein content variability between batches of product. The discrepancy between protein content estimates derived from the Bradford and the HPLC methods are primarily due to differing analytical methodology. Total protein content estimates (as determined by the Bradford assay) for the six batches of u-HMG 75 IU varied by 24.6%. This variability may have been due to the between-batch variability of the gonadotrophin protein and co-purified proteins present, although a larger number of batches would need to be tested to confirm this.
Urine-derived gonadotrophin preparations contain both intact FSH dimers and inactive FSH subunits. Therefore, analytical methods may not fully capture the level of biological activity provided by the FSH molecules present in the final product. For any pharmaceutical gonadotrophin preparation, the Steelman Pohley in-vivo bioassay is the standard method for determining the FSH content based on the activity of the molecule. Using this bioassay, the delivered biological dose of FSH obtained from u-HMG batches demonstrated low variability (3%), but with only 85% of the 75 IU labelled potency. Similarly, the delivered FSH dose for u-hFSH also showed only 88% recovery of the labelled potency of 75 IU.
The major barrier to improving the quality of urine-derived gonadotrophins is at the level of control of the raw material, pooled menopausal urine. This is extremely challenging, as it is dependent on individual contributors. Furthermore, any variation in the purification process, however slight, will inevitably produce batches of urinary gonadotrophins that vary in the concentration and nature of each contaminant. This combination of variability from both source and during processing may lead to the between-batch variability of impurity composition reported, and which was particularly evident for u-HMG.
In addition to revealing the identity of all contaminant proteins present in a complex mixture, current technologies allow the accurate quantification of contaminants in each individual batch of purified urinary gonadotrophins. Larger studies assessing a greater number of batches of gonadotrophin preparations and utilizing similar protein quantification methodology will reveal the true extent of any compositional variability of urinaryderived gonadotrophin products.
In conclusion, recent developments in laboratory analytical techniques can enable a more detailed assessment of gonadotrophin preparations used for multi-follicular stimulation than was previously possible. This study showed that both u-HMG and u-hFSH are highly oxidized, and contain variable and inconsistent concentrations of urine-derived co-purified proteins. In contrast, the recombinant production process results in a pure FSH preparation with no urine-derived proteins, and with a low oxidation level.
